Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has been shown to improve cardiorenal outcomes in patients with T2D and CKD; however, limited data are available regarding the mechanisms of cardiorenal clinical benefits of finerenone. This evidence concerns the gene NR3C2 and type 2 diabetes mellitus.